John H. Rex mostly deals with Mycosis, Fluconazole, Microbiology, Amphotericin B and Internal medicine. His Mycosis study is concerned with the larger field of Immunology. His Fluconazole research includes elements of Itraconazole and Fungemia.
His Amphotericin B study integrates concerns from other disciplines, such as Anesthesia, Catheter, Intensive care medicine, Comparative trial and Pharmacology. The study incorporates disciplines such as Primary therapy, Cancer and Cryptococcus neoformans in addition to Intensive care medicine. The various areas that John H. Rex examines in his Internal medicine study include Gastroenterology and Surgery.
The scientist’s investigation covers issues in Microbiology, Fluconazole, Amphotericin B, Intensive care medicine and Mycosis. His Fluconazole study combines topics in areas such as Itraconazole, Candida glabrata and Pharmacotherapy. His Amphotericin B research focuses on Pharmacology and how it connects with Drug resistance.
John H. Rex has included themes like Invasive candidiasis, Antifungal, Clinical trial and MEDLINE in his Intensive care medicine study. His studies deal with areas such as Internal medicine and Aspergillosis as well as Mycosis. His Internal medicine research incorporates elements of Gastroenterology and Surgery.
His primary scientific interests are in Antibiotic resistance, Risk analysis, Biotechnology, Drug resistance and Microbiology. John H. Rex combines subjects such as Economic growth, Antibiotics, Clinical trial, General partnership and Portfolio with his study of Biotechnology. John H. Rex interconnects Pharmacokinetics, Drug development, Intensive care medicine, Pathogenic organism and Antifungal drug in the investigation of issues within Drug resistance.
His research integrates issues of White paper, Antimicrobial and MEDLINE in his study of Intensive care medicine. His Microbiology research includes themes of In vitro and Trichosporon. His work in Aspergillus covers topics such as Scedosporium which are related to areas like Amphotericin B.
John H. Rex focuses on Biotechnology, Antibiotic resistance, Drug resistance, Economic growth and General partnership. His Biotechnology research is multidisciplinary, incorporating elements of Antibiotics, Clinical trial, Antimicrobial, Intensive care medicine and Portfolio. John H. Rex performs multidisciplinary study in Intensive care medicine and Active control in his work.
His work carried out in the field of Antibiotic resistance brings together such families of science as Antimycobacterial, Mycobacterium tuberculosis and Mode of action. Drug resistance is a subfield of Microbiology that he studies. His work on Reimbursement and Health care as part of general Economic growth study is frequently connected to Scale, Incentive and Health law, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.
Peter G. Pappas;Carol A. Kauffman;David Andes;Daniel K. Benjamin.
Clinical Infectious Diseases (2009)
Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus
S. Ascioglu;J. H. Rex;B. de Pauw;J. E. Bennett.
Clinical Infectious Diseases (2002)
Guidelines for Treatment of Candidiasis
Peter G. Pappas;John H. Rex;Jack D. Sobel;Scott G. Filler.
Clinical Infectious Diseases (2004)
Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections
John H. Rex;Michael A. Pfaller;John N. Galgiani;Marilyn S. Bartlett.
Clinical Infectious Diseases (1997)
Practice Guidelines for the Treatment of Candidiasis
John H. Rex;Thomas J. Walsh;Jack D. Sobel;Scott G. Filler.
Clinical Infectious Diseases (2000)
A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia
John H. Rex;John E. Bennett;Alan M. Sugar;Peter G. Pappas.
The New England Journal of Medicine (1994)
RESISTANCE OF CANDIDA SPECIES TO FLUCONAZOLE
J H Rex;M G Rinaldi;M A Pfaller.
Antimicrobial Agents and Chemotherapy (1995)
A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.
Peter G. Pappas;John H. Rex;Jeannette Lee;Richard J. Hamill.
Clinical Infectious Diseases (2003)
β-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome
Zekaver Odabasi;Gloria Mattiuzzi;Elihu Estey;Hagop Kantarjian.
Clinical Infectious Diseases (2004)
Multicenter Clinical Evaluation of the (1→3) β-D-Glucan Assay as an Aid to Diagnosis of Fungal Infections in Humans
Luis Ostrosky-Zeichner;Barbara D. Alexander;Daniel H. Kett;Jose Antonio Vazquez.
Clinical Infectious Diseases (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: